

**Supplementary Table 1.** Details of the 11 patients with local recurrence. Clinical factors for cases with local recurrence during follow-up are summarized

Case number	Age (years)	FIGO stage (2018)	Histological sub-types	Initial tumor size (cm)	Tumor size at IGBT (cm)	Tumor reduction ratio (%)	Overall treatment time (days)	Total HR-CTV D90 (EQD <sub>2</sub> ), Gy	Time to recurrence (months)	Residual tumor (persistent disease)
1	54	4A	Ad	4.0	3.5	12.5	48	65.6	12.6	No
2	52	2B	Ad	5.2	4.6	11.5	47	80.2	17.6	Yes
3	77	3C2	Ad	5.7	4.8	15.8	55	65.6	27.8	No
4	51	3B	Ad	5.7	4.8	15.8	45	77.5	8.1	Yes
5	64	3B	Ad	5.6	4.9	12.5	51	75.3	11.2	No
6	66	2B	Ad	5.8	4.4	24.1	51	79.7	8.4	No
7	65	3C2	Ad	14.5	10.3	29.0	48	57.4	6.4	Yes
8	67	2B	Ad	6.2	4.1	33.9	54	78.9	18.9	No
9	48	3C1	Adsq	5.0	4.0	20.0	41	96.0	6.2	No
10	48	3C1	Ad	5.2	4.0	23.1	46	76.7	6.3	Yes
11	46	3C1	Adsq	5.0	3.7	26.0	47	54.9	4.8	Yes

FIGO – International Federation of Gynecology and Obstetrics; IGBT – image-guided brachytherapy; HR-CTV – high-risk clinical target volume; EQD<sub>2</sub> – equivalent dose of 2 Gy per fraction; Ad – adenocarcinoma; Adsq – adenosquamous carcinoma